Compare DFLI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | KZIA |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 56.8M |
| IPO Year | N/A | 2002 |
| Metric | DFLI | KZIA |
|---|---|---|
| Price | $2.49 | $6.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $22.50 | $17.67 |
| AVG Volume (30 Days) | ★ 450.0K | 223.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.85 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.64 |
| 52 Week High | $5.15 | $17.40 |
| Indicator | DFLI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 46.80 |
| Support Level | $2.16 | $4.91 |
| Resistance Level | $2.88 | $6.34 |
| Average True Range (ATR) | 0.29 | 0.56 |
| MACD | -0.03 | 0.11 |
| Stochastic Oscillator | 68.45 | 66.69 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.